abmd-10q_20200930.htm
false 2021 Q2 0000815094 --03-31 P2Y P3Y 2019-10-15 2024-10-15 85000000 2019-10-15 2024-10-15 93457000 P4Y11M26D P5Y3M18D P5Y9M7D P4Y10M2D P5Y9M7D P4Y2M1D P4Y1M17D P4Y2M19D P4Y1M20D P1Y10M24D 347.05 P2Y10M24D 349.28 0000815094 2020-04-01 2020-09-30 xbrli:shares 0000815094 2020-10-22 iso4217:USD 0000815094 2020-09-30 0000815094 2020-03-31 iso4217:USD xbrli:shares 0000815094 2020-07-01 2020-09-30 0000815094 2019-07-01 2019-09-30 0000815094 2019-04-01 2019-09-30 0000815094 us-gaap:CommonStockMember 2020-03-31 0000815094 us-gaap:TreasuryStockMember 2020-03-31 0000815094 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000815094 us-gaap:RetainedEarningsMember 2020-03-31 0000815094 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000815094 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000815094 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000815094 2020-04-01 2020-06-30 0000815094 us-gaap:TreasuryStockMember 2020-04-01 2020-06-30 0000815094 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000815094 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000815094 us-gaap:CommonStockMember 2020-06-30 0000815094 us-gaap:TreasuryStockMember 2020-06-30 0000815094 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000815094 us-gaap:RetainedEarningsMember 2020-06-30 0000815094 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000815094 2020-06-30 0000815094 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000815094 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000815094 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000815094 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000815094 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000815094 us-gaap:CommonStockMember 2020-09-30 0000815094 us-gaap:TreasuryStockMember 2020-09-30 0000815094 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000815094 us-gaap:RetainedEarningsMember 2020-09-30 0000815094 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000815094 us-gaap:CommonStockMember 2019-03-31 0000815094 us-gaap:TreasuryStockMember 2019-03-31 0000815094 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000815094 us-gaap:RetainedEarningsMember 2019-03-31 0000815094 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000815094 2019-03-31 0000815094 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000815094 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000815094 2019-04-01 2019-06-30 0000815094 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0000815094 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000815094 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000815094 us-gaap:CommonStockMember 2019-06-30 0000815094 us-gaap:TreasuryStockMember 2019-06-30 0000815094 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000815094 us-gaap:RetainedEarningsMember 2019-06-30 0000815094 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000815094 2019-06-30 0000815094 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000815094 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000815094 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0000815094 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000815094 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000815094 us-gaap:CommonStockMember 2019-09-30 0000815094 us-gaap:TreasuryStockMember 2019-09-30 0000815094 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000815094 us-gaap:RetainedEarningsMember 2019-09-30 0000815094 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000815094 2019-09-30 0000815094 us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-09-30 0000815094 abmd:BreetheIncAcquisitionMember 2020-04-01 2020-04-30 0000815094 abmd:BreetheIncAcquisitionMember srt:MaximumMember 2020-04-30 0000815094 2020-04-23 2020-04-24 0000815094 2020-04-24 0000815094 abmd:ImpellaProductMember 2020-07-01 2020-09-30 0000815094 abmd:ImpellaProductMember 2019-07-01 2019-09-30 0000815094 abmd:ImpellaProductMember 2020-04-01 2020-09-30 0000815094 abmd:ImpellaProductMember 2019-04-01 2019-09-30 0000815094 abmd:ServiceAndOtherMember 2020-07-01 2020-09-30 0000815094 abmd:ServiceAndOtherMember 2019-07-01 2019-09-30 0000815094 abmd:ServiceAndOtherMember 2020-04-01 2020-09-30 0000815094 abmd:ServiceAndOtherMember 2019-04-01 2019-09-30 0000815094 country:US 2020-07-01 2020-09-30 0000815094 country:US 2019-07-01 2019-09-30 0000815094 country:US 2020-04-01 2020-09-30 0000815094 country:US 2019-04-01 2019-09-30 0000815094 us-gaap:NonUsMember 2020-07-01 2020-09-30 0000815094 us-gaap:NonUsMember 2019-07-01 2019-09-30 0000815094 us-gaap:NonUsMember 2020-04-01 2020-09-30 0000815094 us-gaap:NonUsMember 2019-04-01 2019-09-30 0000815094 us-gaap:MoneyMarketFundsMember us-gaap:CashEquivalentsMember 2020-09-30 0000815094 us-gaap:RepurchaseAgreementsMember us-gaap:CashEquivalentsMember 2020-09-30 0000815094 us-gaap:CashEquivalentsMember 2020-09-30 0000815094 us-gaap:USTreasurySecuritiesMember us-gaap:ShortTermInvestmentsMember 2020-09-30 0000815094 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2020-09-30 0000815094 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2020-09-30 0000815094 us-gaap:CommercialPaperMember us-gaap:ShortTermInvestmentsMember 2020-09-30 0000815094 us-gaap:ShortTermInvestmentsMember 2020-09-30 0000815094 us-gaap:USTreasurySecuritiesMember abmd:LongTermInvestmentsMember 2020-09-30 0000815094 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember abmd:LongTermInvestmentsMember 2020-09-30 0000815094 us-gaap:CorporateDebtSecuritiesMember abmd:LongTermInvestmentsMember 2020-09-30 0000815094 abmd:LongTermInvestmentsMember 2020-09-30 0000815094 us-gaap:MoneyMarketFundsMember us-gaap:CashEquivalentsMember 2020-03-31 0000815094 us-gaap:RepurchaseAgreementsMember us-gaap:CashEquivalentsMember 2020-03-31 0000815094 us-gaap:CashEquivalentsMember 2020-03-31 0000815094 us-gaap:USTreasurySecuritiesMember us-gaap:ShortTermInvestmentsMember 2020-03-31 0000815094 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2020-03-31 0000815094 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermInvestmentsMember 2020-03-31 0000815094 us-gaap:CommercialPaperMember us-gaap:ShortTermInvestmentsMember 2020-03-31 0000815094 us-gaap:ShortTermInvestmentsMember 2020-03-31 0000815094 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember abmd:LongTermInvestmentsMember 2020-03-31 0000815094 us-gaap:CorporateDebtSecuritiesMember abmd:LongTermInvestmentsMember 2020-03-31 0000815094 abmd:LongTermInvestmentsMember 2020-03-31 iso4217:EUR 0000815094 us-gaap:CrossCurrencyInterestRateContractMember 2020-09-30 0000815094 abmd:InternationalMember 2019-10-31 0000815094 currency:EUR 2020-04-01 2020-09-30 0000815094 currency:USD 2020-04-01 2020-09-30 xbrli:pure 0000815094 currency:EUR 2020-09-30 0000815094 currency:USD 2020-09-30 0000815094 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:OtherAssetsMember 2020-09-30 0000815094 abmd:EcpMember 2020-09-30 0000815094 abmd:EcpMember 2020-03-31 0000815094 abmd:BreetheIncAcquisitionMember 2020-09-30 0000815094 abmd:EcpMember 2014-07-02 2014-07-31 0000815094 abmd:EcpMember 2014-07-31 0000815094 abmd:EcpMember srt:MinimumMember 2020-09-30 0000815094 abmd:EcpMember srt:MaximumMember 2020-09-30 0000815094 abmd:EcpMember 2020-04-01 2020-09-30 0000815094 abmd:BreetheIncAcquisitionMember srt:MinimumMember 2020-09-30 0000815094 abmd:BreetheIncAcquisitionMember srt:MaximumMember 2020-09-30 0000815094 abmd:BreetheIncAcquisitionMember srt:MinimumMember 2020-04-01 2020-09-30 0000815094 abmd:BreetheIncAcquisitionMember srt:MaximumMember 2020-04-01 2020-09-30 0000815094 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-09-30 0000815094 us-gaap:MoneyMarketFundsMember 2020-09-30 0000815094 us-gaap:FairValueInputsLevel2Member us-gaap:RepurchaseAgreementsMember 2020-09-30 0000815094 us-gaap:RepurchaseAgreementsMember 2020-09-30 0000815094 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermInvestmentsMember 2020-09-30 0000815094 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermInvestmentsMember 2020-09-30 0000815094 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:ShortTermInvestmentsMember 2020-09-30 0000815094 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermInvestmentsMember 2020-09-30 0000815094 abmd:LongTermUSTreasuryMutualFundSecuritiesMember us-gaap:FairValueInputsLevel2Member 2020-09-30 0000815094 abmd:LongTermUSTreasuryMutualFundSecuritiesMember 2020-09-30 0000815094 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member abmd:LongTermInvestmentsMember 2020-09-30 0000815094 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member abmd:LongTermInvestmentsMember 2020-09-30 0000815094 us-gaap:FairValueInputsLevel1Member abmd:ShockwaveMedicalMember 2020-09-30 0000815094 abmd:ShockwaveMedicalMember 2020-09-30 0000815094 us-gaap:FairValueInputsLevel3Member 2020-09-30 0000815094 us-gaap:FairValueInputsLevel2Member us-gaap:CrossCurrencyInterestRateContractMember 2020-09-30 0000815094 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-03-31 0000815094 us-gaap:MoneyMarketFundsMember 2020-03-31 0000815094 us-gaap:FairValueInputsLevel2Member us-gaap:RepurchaseAgreementsMember 2020-03-31 0000815094 us-gaap:RepurchaseAgreementsMember 2020-03-31 0000815094 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermInvestmentsMember 2020-03-31 0000815094 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermInvestmentsMember 2020-03-31 0000815094 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:ShortTermInvestmentsMember 2020-03-31 0000815094 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:ShortTermInvestmentsMember 2020-03-31 0000815094 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member abmd:LongTermInvestmentsMember 2020-03-31 0000815094 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member abmd:LongTermInvestmentsMember 2020-03-31 0000815094 us-gaap:FairValueInputsLevel2Member us-gaap:CrossCurrencyInterestRateContractMember 2020-03-31 0000815094 us-gaap:CrossCurrencyInterestRateContractMember 2020-03-31 0000815094 us-gaap:FairValueInputsLevel1Member abmd:ShockwaveMedicalMember 2020-03-31 0000815094 abmd:ShockwaveMedicalMember 2020-03-31 0000815094 us-gaap:FairValueInputsLevel3Member 2020-03-31 0000815094 us-gaap:FairValueInputsLevel3Member abmd:EcpEntwickslungsgesellschaftMbhMember abmd:ContingentConsiderationMember 2020-06-30 0000815094 us-gaap:FairValueInputsLevel3Member abmd:EcpEntwickslungsgesellschaftMbhMember abmd:ContingentConsiderationMember 2019-06-30 0000815094 us-gaap:FairValueInputsLevel3Member abmd:EcpEntwickslungsgesellschaftMbhMember abmd:ContingentConsiderationMember 2020-03-31 0000815094 us-gaap:FairValueInputsLevel3Member abmd:EcpEntwickslungsgesellschaftMbhMember abmd:ContingentConsiderationMember 2019-03-31 0000815094 us-gaap:FairValueInputsLevel3Member abmd:EcpEntwickslungsgesellschaftMbhMember abmd:ContingentConsiderationMember 2020-07-01 2020-09-30 0000815094 us-gaap:FairValueInputsLevel3Member abmd:EcpEntwickslungsgesellschaftMbhMember abmd:ContingentConsiderationMember 2019-07-01 2019-09-30 0000815094 us-gaap:FairValueInputsLevel3Member abmd:EcpEntwickslungsgesellschaftMbhMember abmd:ContingentConsiderationMember 2020-04-01 2020-09-30 0000815094 us-gaap:FairValueInputsLevel3Member abmd:EcpEntwickslungsgesellschaftMbhMember abmd:ContingentConsiderationMember 2019-04-01 2019-09-30 0000815094 us-gaap:FairValueInputsLevel3Member abmd:EcpEntwickslungsgesellschaftMbhMember abmd:ContingentConsiderationMember 2020-09-30 0000815094 us-gaap:FairValueInputsLevel3Member abmd:EcpEntwickslungsgesellschaftMbhMember abmd:ContingentConsiderationMember 2019-09-30 0000815094 abmd:BreetheIncAcquisitionMember 2020-04-01 2020-09-30 0000815094 abmd:EcpEntwickslungsgesellschaftMbhMember 2020-09-30 0000815094 abmd:EcpEntwickslungsgesellschaftMbhMember 2020-03-31 0000815094 abmd:EcpEntwickslungsgesellschaftMbhMember srt:MaximumMember us-gaap:MeasurementInputDiscountRateMember 2020-09-30 0000815094 abmd:EcpEntwickslungsgesellschaftMbhMember srt:MinimumMember us-gaap:MeasurementInputDiscountRateMember 2020-09-30 0000815094 abmd:ShockwaveMedicalMember 2020-07-01 2020-09-30 0000815094 abmd:ShockwaveMedicalMember us-gaap:OtherIncomeMember 2020-07-01 2020-09-30 0000815094 abmd:ShockwaveMedicalMember us-gaap:OtherIncomeMember 2020-04-01 2020-09-30 0000815094 abmd:ShockwaveMedicalMember us-gaap:OtherIncomeMember 2019-07-01 2019-09-30 0000815094 abmd:ShockwaveMedicalMember us-gaap:OtherIncomeMember 2019-04-01 2019-09-30 0000815094 us-gaap:OtherIncomeMember 2020-07-01 2020-09-30 0000815094 us-gaap:OtherIncomeMember 2020-04-01 2020-09-30 0000815094 abmd:LicenseManufacturingRightsToTechnologyMember 2020-04-01 2020-09-30 0000815094 us-gaap:OtherIntangibleAssetsMember 2020-04-01 2020-09-30 0000815094 2019-08-31 0000815094 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-31 0000815094 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-03-31 0000815094 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-03-31 0000815094 us-gaap:AccumulatedTranslationAdjustmentMember 2020-04-01 2020-06-30 0000815094 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-04-01 2020-06-30 0000815094 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-04-01 2020-06-30 0000815094 us-gaap:AccumulatedTranslationAdjustmentMember 2020-06-30 0000815094 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-06-30 0000815094 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-06-30 0000815094 us-gaap:AccumulatedTranslationAdjustmentMember 2020-07-01 2020-09-30 0000815094 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-07-01 2020-09-30 0000815094 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2020-09-30 0000815094 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 0000815094 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-09-30 0000815094 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-09-30 0000815094 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-31 0000815094 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-03-31 0000815094 us-gaap:AccumulatedTranslationAdjustmentMember 2019-04-01 2019-06-30 0000815094 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-04-01 2019-06-30 0000815094 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0000815094 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-06-30 0000815094 us-gaap:AccumulatedTranslationAdjustmentMember 2019-07-01 2019-09-30 0000815094 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-07-01 2019-09-30 0000815094 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0000815094 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-09-30 0000815094 us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0000815094 us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0000815094 us-gaap:CostOfSalesMember 2020-04-01 2020-09-30 0000815094 us-gaap:CostOfSalesMember 2019-04-01 2019-09-30 0000815094 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0000815094 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0000815094 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-09-30 0000815094 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-09-30 0000815094 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0000815094 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0000815094 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-04-01 2020-09-30 0000815094 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-09-30 0000815094 2018-04-01 2019-03-31 0000815094 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-09-30 0000815094 us-gaap:EmployeeStockOptionMember 2020-09-30 0000815094 us-gaap:EmployeeStockOptionMember 2020-07-01 2020-09-30 0000815094 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0000815094 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-09-30 0000815094 us-gaap:RestrictedStockUnitsRSUMember 2020-03-31 0000815094 us-gaap:RestrictedStockUnitsRSUMember 2020-09-30 0000815094 abmd:PerformanceBasedRestrictedStockUnitsMember srt:MaximumMember 2020-05-01 2020-05-31 0000815094 abmd:MarketBasedAwardsMember 2020-05-01 2020-05-31 0000815094 abmd:MarketBasedAwardsMember srt:MinimumMember 2020-05-01 2020-05-31 0000815094 abmd:MarketBasedAwardsMember srt:MaximumMember 2020-05-01 2020-05-31 0000815094 srt:MinimumMember 2020-04-01 2020-09-30 0000815094 srt:MaximumMember 2020-04-01 2020-09-30 0000815094 srt:MinimumMember 2020-09-30 0000815094 srt:MaximumMember 2020-09-30 abmd:Segment 0000815094 abmd:InternationalMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-07-01 2020-09-30 0000815094 abmd:InternationalMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-07-01 2019-09-30 0000815094 abmd:InternationalMember 2020-09-30 0000815094 abmd:InternationalMember 2020-03-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                      

Commission file number: 001-09585

 

ABIOMED, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

04-2743260

(State or other jurisdiction of incorporation or organization)

 

(IRS Employer Identification No.)

22 CHERRY HILL DRIVE

Danvers, Massachusetts 01923

(Address of principal executive offices, including zip code)

(978) 646-1400

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol

Name of each exchange on which registered

Common Stock, $0.01 par value

ABMD

The NASDAQ Stock Market LLC

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

As of October 22, 2020, 45,189,883 shares of the registrant’s common stock, $.01 par value, were outstanding.

 

 

 

 

 


 

TABLE OF CONTENTS

 

PART I - FINANCIAL INFORMATION:

Page

 

 

 

Item 1.

Condensed Consolidated Financial Statements (unaudited)

3

 

 

 

 

Condensed Consolidated Balance Sheets as of September 30, 2020 and March 31, 2020

3

 

 

 

 

Condensed Consolidated Statements of Operations for the three and six months ended September 30, 2020 and 2019

4

 

 

 

 

Condensed Consolidated Statements of Comprehensive Income for the three and six months ended September 30, 2020 and 2019

5

 

 

 

 

Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended September 30, 2020 and 2019

6

 

 

 

 

Condensed Consolidated Statements of Cash Flows for the six months ended September 30, 2020 and 2019

7

 

 

 

 

Notes to Condensed Consolidated Financial Statements (unaudited)

8

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

27

 

 

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

36

 

 

 

Item 4.

Controls and Procedures

36

 

 

 

PART II - OTHER INFORMATION:

 

 

 

 

Item 1.

Legal Proceedings

37

 

 

 

Item 1A.

Risk Factors

37

 

 

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

37

 

 

 

Item 3.

Defaults Upon Senior Securities

37

 

 

 

Item 4.

Mine Safety Disclosures

37

 

 

 

Item 5.

Other Information

37

 

 

 

Item 6.

Exhibits

38

 

 

 

Signatures

39

 

 

EXPLANATORY NOTES

Pending Trademarks and Registered Marks

Throughout this quarterly report on Form 10-Q (“this Report”), we refer to various trademarks, service marks and trade names that we use in our business. Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, Impella 5.5, Impella Connect, and SmartAssist are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries. Impella ECP, Impella XR Sheath, Impella BTR, CVAD, STEMI DTU, Automated Impella Controller and Abiomed Breethe OXY-1 System are pending trademarks of Abiomed, Inc. Other trademarks and service marks appearing in this Report are the property of their respective holders.

Company References

Throughout this Report, “ABIOMED, Inc.,” the “Company,” “we,” “us” and “our” refer to ABIOMED, Inc. and its consolidated subsidiaries.

Where You Can Find More Information

We make available, free of charge on our website located at www.abiomed.com, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to those reports, as soon as reasonably practicable after filing such reports with or furnishing such reports to the U.S. Securities and Exchange Commission (“SEC”). We also use our website for the distribution of Company information. The information we post on our website may be deemed to be material information. Accordingly, investors should monitor our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. The contents of our website are not incorporated by reference into this Report.  

2


 

PART I. FINANCIAL INFORMATION

ITEM 1: Condensed Consolidated Financial Statements

ABIOMED, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except share data)

 

 

 

September 30, 2020

 

 

March 31, 2020

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

202,241

 

 

$

192,341

 

Short-term marketable securities

 

 

330,843

 

 

 

250,775

 

Accounts receivable, net

 

 

80,909

 

 

 

84,650

 

Inventories

 

 

83,209

 

 

 

90,088

 

Prepaid expenses and other current assets

 

 

19,419

 

 

 

18,009

 

Total current assets

 

 

716,621

 

 

 

635,863

 

Long-term marketable securities

 

 

202,613

 

 

 

207,795

 

Property and equipment, net

 

 

175,582

 

 

 

164,931

 

Goodwill

 

 

78,122

 

 

 

31,969

 

In-process research and development

 

 

42,895

 

 

 

14,913

 

Deferred tax assets

 

 

29,547

 

 

 

43,336

 

Other assets

 

 

82,594

 

 

 

117,655

 

Total assets

 

$

1,327,974

 

 

$

1,216,462

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

21,734

 

 

$

32,774

 

Accrued expenses

 

 

57,227

 

 

 

75,107

 

Deferred revenue

 

 

21,314

 

 

 

19,147

 

Other current liabilities

 

 

4,938

 

 

 

4,857

 

Total current liabilities

 

 

105,213

 

 

 

131,885

 

Contingent consideration

 

 

24,417

 

 

 

9,000

 

Deferred tax liabilities

 

 

4,251

 

 

 

806

 

Other long-term liabilities

 

 

11,684

 

 

 

9,305

 

Total liabilities

 

 

145,565

 

 

 

150,996

 

Commitments and contingencies (Note 14)

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Class B Preferred Stock, $.01 par value

 

 

 

 

 

 

Authorized - 1,000,000 shares; Issued and outstanding - none

 

 

 

 

 

 

 

 

Common stock, $.01 par value

 

 

452

 

 

 

451

 

Authorized - 100,000,000 shares; Issued - 47,847,023 shares at September 30, 2020 and 47,542,061 shares at March 31, 2020

 

 

 

 

 

 

 

 

Outstanding - 45,189,883 shares at September 30, 2020 and 45,008,687 shares at March 31, 2020

 

 

 

 

 

 

 

 

Additional paid in capital

 

 

767,527

 

 

 

739,133

 

Retained earnings

 

 

709,283

 

 

 

602,482

 

Treasury stock at cost - 2,657,140 shares at September 30, 2020 and 2,533,374 shares at March 31, 2020

 

 

(287,654

)

 

 

(265,411

)

Accumulated other comprehensive loss

 

 

(7,199

)

 

 

(11,189

)

Total stockholders' equity

 

 

1,182,409

 

 

 

1,065,466

 

Total liabilities and stockholders' equity

 

$

1,327,974

 

 

$

1,216,462

 

 

The accompanying notes are an integral part of the condensed consolidated financial statements (unaudited)

 

3


 

ABIOMED, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except per share data)

 

 

 

For the Three Months Ended September 30,

 

 

For the Six Months Ended September 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Revenue

 

$

209,764

 

 

$

204,974

 

 

$

374,614

 

 

$

412,640

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenue

 

 

38,736

 

 

 

34,867

 

 

 

74,719

 

 

 

71,940

 

Research and development

 

 

30,525

 

 

 

23,969

 

 

 

56,882

 

 

 

47,759

 

Selling, general and administrative

 

 

79,167

 

 

 

85,956

 

 

 

147,611

 

 

 

172,034

 

 

 

 

148,428

 

 

 

144,792

 

 

 

279,212

 

 

 

291,733

 

Income from operations

 

 

61,336

 

 

 

60,182

 

 

 

95,402

 

 

 

120,907

 

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Investment income, net

 

 

1,822

 

 

 

2,932

 

 

 

4,219

 

 

 

5,981

 

Other income (expense), net

 

 

9,757

 

 

 

(45,756

)

 

 

34,370

 

 

 

(6,392

)

 

 

 

11,579

 

 

 

(42,824

)

 

 

38,589

 

 

 

(411

)

Income before income taxes

 

 

72,915

 

 

 

17,358

 

 

 

133,991

 

 

 

120,496

 

Income tax provision

 

 

10,702

 

 

 

4,287

 

 

 

27,190

 

 

 

18,502

 

Net income

 

$

62,213

 

 

$

13,071

 

 

$

106,801

 

 

$

101,994

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic net income per share

 

$

1.38

 

 

$

0.29

 

 

$

2.37

 

 

$

2.25

 

Basic weighted average shares outstanding

 

 

45,104

 

 

 

45,319

 

 

 

45,057

 

 

 

45,267

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted net income per share

 

$

1.36

 

 

$

0.28

 

 

$

2.34

 

 

$

2.22

 

Diluted weighted average shares outstanding

 

 

45,661

 

 

 

45,912

 

 

 

45,609

 

 

 

46,031

 

 

The accompanying notes are an integral part of the condensed consolidated financial statements (unaudited)

 

4


 

ABIOMED, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Income (Unaudited)

(in thousands)

 

 

 

For the Three Months Ended September 30,

 

 

For the Six Months Ended September 30,

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Net income

 

$

62,213

 

 

$

13,071

 

 

$

106,801

 

 

$

101,994

 

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation gains (losses)

 

 

2,416

 

 

 

(5,716

)

 

 

3,776

 

 

 

(3,382

)

Unrealized losses on derivative instrument

 

 

(266

)

 

 

 

 

 

(726

)

 

 

 

Net unrealized (losses) gains on marketable securities

 

 

(814

)

 

 

(85

)

 

 

940

 

 

 

515

 

Other comprehensive income

 

 

1,336

 

 

 

(5,801

)

 

 

3,990

 

 

 

(2,867

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive income

 

$

63,549

 

 

$

7,270

 

 

$

110,791

 

 

$

99,127

 

 

The accompanying notes are an integral part of the condensed consolidated financial statements (unaudited)

 

 

 

 

5


 

ABIOMED, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)

(in thousands, except share data)

 

 

 

Common Stock

 

 

Treasury Stock

 

 

Additional Paid

 

 

Retained

 

 

Accumulated Other

 

 

Total Stockholders'

 

 

 

Shares

 

 

Par value

 

 

Shares

 

 

Amount

 

 

in Capital

 

 

Earnings

 

 

Comprehensive Loss

 

 

Equity

 

Balance, April 1, 2020

 

 

45,008,687

 

 

$

451

 

 

 

2,533,374

 

 

$

(265,411

)

 

$

739,133

 

 

$

602,482

 

 

$

(11,189

)

 

$

1,065,466

 

Restricted stock units issued

 

 

124,749

 

 

 

1

 

 

 

 

 

 

 

 

 

(1

)

 

 

 

 

 

 

 

 

 

Stock options exercised

 

 

31,488

 

 

 

 

 

 

 

 

 

 

 

 

1,010

 

 

 

 

 

 

 

 

 

1,010

 

Return of common stock to pay withholding taxes on restricted stock

 

 

(52,515

)

 

 

 

 

 

52,515

 

 

 

(9,857

)

 

 

 

 

 

 

 

 

 

 

 

(9,857

)

Stock compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

9,298

 

 

 

 

 

 

 

 

 

9,298

 

Stock repurchase program

 

 

(67,649

)

 

 

(1

)

 

 

67,649

 

 

 

(11,309

)

 

 

 

 

 

 

 

 

 

 

 

(11,310

)

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,654

 

 

 

2,654

 

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

44,588

 

 

 

 

 

 

44,588

 

Balance, June 30, 2020

 

 

45,044,760

 

 

$

450

 

 

 

2,653,538

 

 

$

(286,577

)

 

$

749,440

 

 

$

647,070

 

 

$

(8,535

)

 

$

1,101,848

 

Restricted stock units issued

 

 

11,554

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock options exercised

 

 

121,066

 

 

 

1

 

 

 

 

 

 

 

 

 

4,544

 

 

 

 

 

 

 

 

 

4,545

 

Return of common stock to pay withholding taxes on restricted stock

 

 

(3,602

)

 

 

 

 

 

3,602

 

 

 

(1,077

)

 

 

 

 

 

 

 

 

 

 

 

(1,077

)

Stock issued under employee stock purchase plan

 

 

16,105

 

 

 

1

 

 

 

 

 

 

 

 

 

1,978

 

 

 

 

 

 

 

 

 

1,979

 

Stock compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

11,565

 

 

 

 

 

 

 

 

 

11,565

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,336

 

 

 

1,336

 

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

62,213

 

 

 

 

 

 

62,213

 

Balance, September 30, 2020

 

 

45,189,883

 

 

$

452

 

 

 

2,657,140

 

 

$

(287,654

)

 

$

767,527

 

 

$

709,283

 

 

$

(7,199

)

 

$

1,182,409

 

 

 

 

 

Common Stock

 

 

Treasury Stock

 

 

Additional Paid

 

 

Retained

 

 

Accumulated Other

 

 

Total Stockholders'

 

 

 

Shares

 

 

Par value

 

 

Shares

 

 

Amount

 

 

in Capital

 

 

Earnings

 

 

Comprehensive Loss

 

 

Equity

 

Balance, April 1, 2019

 

 

45,122,985

 

 

$

451

 

 

 

1,903,241

 

 

$

(138,852

)

 

$

690,507

 

 

$

399,473

 

 

$

(14,689

)

 

$

936,890

 

Restricted stock units issued

 

 

373,430

 

 

 

4

 

 

 

 

 

 

 

 

 

(4

)

 

 

 

 

 

 

 

 

 

Stock options exercised

 

 

36,289

 

 

 

1

 

 

 

 

 

 

 

 

 

1,260

 

 

 

 

 

 

 

 

 

1,261

 

Return of common stock to pay withholding taxes on restricted stock

 

 

(158,426

)

 

 

(2

)

 

 

158,426

 

 

 

(40,534

)

 

 

 

 

 

 

 

 

 

 

 

(40,536

)

Stock compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

13,121

 

 

 

 

 

 

 

 

 

13,121

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,934

 

 

 

2,934

 

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

88,923

 

 

 

 

 

 

88,923

 

Balance, June 30, 2019

 

 

45,374,278

 

 

$

454

 

 

 

2,061,667

 

 

$

(179,386

)

 

$

704,884

 

 

$

488,396

 

 

$

(11,755

)

 

$

1,002,593

 

Restricted stock units issued

 

 

12,039

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock options exercised

 

 

21,268

 

 

 

 

 

 

 

 

 

 

 

 

1,445

 

 

 

 

 

 

 

 

 

1,445

 

Return of common stock to pay withholding taxes on restricted stock

 

 

(3,363

)

 

 

 

 

 

3,363

 

 

 

(668